[HIV-2 infection in Senegal: virological failures and resistance to antiretroviral drugs (ARVs)].

Autor:	Ba S; Service des Maladies Infectieuses CHUN de Fann, Dakar, Sénégal., Dia-Badiane NM; Service des Maladies Infectieuses CHUN de Fann, Dakar, Sénégal., Hawes SE; University of Washington, Seattle, USA., Deguenonvo LF; Service des Maladies Infectieuses CHUN de Fann, Dakar, Sénégal., Sall F; Service des Maladies Infectieuses CHUN de Fann, Dakar, Sénégal., Ndour CT; Service des Maladies Infectieuses CHUN de Fann, Dakar, Sénégal., Faye K; Service des Maladies Infectieuses CHUN de Fann, Dakar, Sénégal., Traoré F; Service des Maladies Infectieuses CHUN de Fann, Dakar, Sénégal., Touré M; Service des Maladies Infectieuses CHUN de Fann, Dakar, Sénégal., Sy MP; Service des Maladies Infectieuses CHUN de Fann, Dakar, Sénégal., Raugi DN; Service des Maladies Infectieuses CHUN de Fann, Dakar, Sénégal., Kiviat NB; University of Washington, Seattle, USA., Smith RA; University of Washington, Seattle, USA., Seydi M; Service des Maladies Infectieuses CHUN de Fann, Dakar, Sénégal., Sow PS; Service des Maladies Infectieuses CHUN de Fann, Dakar, Sénégal., Gottlieb GS; University of Washington, Seattle, USA.
Jazyk:	francouzština
Zdroj:	The Pan African medical journal [Pan Afr Med J] 2019 Jul 18; Vol. 33, pp. 222. Date of Electronic Publication: 2019 Jul 18 (Print Publication: 2019).
DOI:	10.11604/pamj.2019.33.222.15771
Abstrakt:	Introduction: HIV-2, endemic in West Africa, has a natural resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) which makes it difficult to treat it in developing countries. Methods: We conducted a descriptive, longitudinal, prospective study over the period November 2005-June 2017. Virologic failure has been defined as any viral load greater than 50 copies/ml after 6 months of ARV treatment administered twice. Assays for detecting drug-resistance mutations was performed in the protease-coding region and in the reverse transcriptase-coding region. Results: Data from a total of 110 patients were collected. The patients had a median age of 46 years (ranging from 18 to 67) with a sex-ratio F/M of 2.54. At inclusion, viral load could be assessed in 44% of cases with a median of 935cp/ml (ranging from 17 to 144038). Antiretroviral regimen consisted of a combination of 2 NRTIs and 1IP in 94% of cases. The median follow-up was 1200 days (ranging from 1 to 3840); 94 then 76 patients completed their 12-month and 24-month assessments respectively. At 24-month follow-up, 39 patients had virologic failure, reflecting a prevalence of 39% estimated at 33% at 12-month follow-up and at 11% at 24-month follow-up; NRTIs resistance was observed in 45% of patients, IP resistance in 41% of patients while multi-NRTIs resistance and multi-IP resistance in 30% of patients. Conclusion: Currently, there is an urgent need to make available the new therapeutic classes of ARV for second line ART for patients living with HIV-2 with therapeutic failure in resource-limited settings. Competing Interests: Les auteurs ne déclarent aucun conflit d’intérêts. (© Selly Ba et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF